Drugs in MeSH Category Contraceptives, Oral, Synthetic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	EMZAHH	norethindrone	TABLET;ORAL-28	216796-001	Jan 6, 2023	AB2	RX	No	No
Novitium Pharma	MEGESTROL ACETATE	megestrol acetate	SUSPENSION;ORAL	077404-001	Feb 16, 2006	AB	RX	No	No
Xiromed	MEDROXYPROGESTERONE ACETATE	medroxyprogesterone acetate	INJECTABLE;INJECTION	210227-001	Oct 12, 2018	AB	RX	No	No
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes
Bristol Myers Squibb	MEGACE	megestrol acetate	SUSPENSION;ORAL	020264-001	Sep 10, 1993		DISCN	Yes	No
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes
Pfizer	PROVERA	medroxyprogesterone acetate	TABLET;ORAL	011839-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Last updated: July 20, 2026

Market dynamics and patent landscape for NLM MeSH Class: Contraceptives, Oral, Synthetic

Oral synthetic contraceptives sit in a mature, high-volume market with recurring patent cliffs driven by the expiration of active-ingredient and formulation families, plus ongoing “evergreening” through dosing regimens, fixed-dose combinations, prodrug/chemical forms, and delivery-specific patents. Near-term competitive pressure is concentrated in jurisdictions where Orange Book style listings and paragraph IV filing histories translate into faster generic entry, while longer-tailed brand endurance typically depends on proprietary combinations, protected indication expansion, and regulatory exclusivity layered on top of patent coverage.

Market structure snapshot (what drives pricing and volume)

• Core competition: Authorized generics and multiple ANDA players for legacy ethinyl estradiol (EE) and progestins, with periodic brand launches of newer progestins or optimized regimens.
• Primary value levers: Reduced pill burden (daily/extended cycles), lower adverse-effect profile claims, and payer/formulary placement anchored to tolerability and “net cost” after rebates.
• Patent-driven dynamics: The majority of patent estate value is concentrated in
  1. active-ingredient composition-of-matter (often early expiration),
  2. fixed-dose combinations (longer-tail),
  3. method-of-use (cycle control, dosing schedules),
  4. formulation/process (unit dosage, film coating, particle engineering, stability),
  5. regulatory exclusivity timing (new formulations or novel dosing approvals in limited subsets).

Because this MeSH class spans many products and actives, the patent landscape is best understood as a set of recurring IP patterns rather than a single estate. Below is a structured view of how the market behaves and where patent risk concentrates for oral synthetic contraceptives.

---

Which oral synthetic contraceptives define the patent and competitive battleground?

Answer: The battleground is dominated by (1) EE plus progestin fixed-dose combinations and (2) extended-cycle or lower-dose branded regimens that attract separate formulation, dosing, and method-of-use protections.

Major active-ingredient clusters that anchor patent estates

• EE + levonorgestrel (LNG) combinations (high legacy generic penetration; brand differentiation often shifts to extended schedules and dosing refinements).
• EE + norgestimate, norethindrone acetate, or norgestrel (repeat formulation/process IP; combination-specific claims matter most).
• Newer progestin families used for cycle control and tolerability narratives:
  • desogestrel, gestodene
  • drospirenone
  • etonogestrel combinations where oral products are involved
• Continuous/extended regimens using triphasic or quadriphasic dosing structures (method-of-use and schedule patents).

How product architecture drives patent scope

• Fixed-dose combinations: Claims usually cover specific EE/progestin ratios, tablet compositions, and stabilizing excipients. Generics face formulation equivalency and method-of-use carveouts depending on how patents are asserted in litigation.
• Triphasic dosing kits: “Packaged schedule” and unit dosage structure claims tend to persist longer than the underlying actives.
• Low-dose or extended-cycle: Separate process claims (manufacturing for stability) and regimen patents (use patterns) are common.

---

How do market dynamics shape generic entry for oral contraceptives?

Answer: Generic entry is fastest for single-entity or older fixed-dose combinations without active litigation leverage, and slower for newer branded combinations with later-expiring formulation and dosing patents.

Generic and biosimilar risk profile (even though these are small molecules)

• These are synthetic small molecules, so “biosimilar risk” is not the framework.
• The practical risk is ANDAs + patent litigation + design-around.
• “Design-around” is common where formulation/process claims exist but composition-of-matter is not asserted or is already expired.

Typical entry timeline mechanics

1. Patent expiration of composition-of-matter and key formulation patents.
2. ANDA filing triggers litigation via Orange Book-listed patents.
3. Automatic stay (if applicable) delays approval until a court decision or settlement.
4. Settlement agreements may impose market-entry dates without a full patent loss.

Where delays come from

• Multiple Orange Book listings per product line can create sequential stays.
• Method-of-use and formulation patents can be harder to “equivalence-walk” because the generic must avoid infringement not only on composition but also on the claimed use.

---

What patents protect oral synthetic contraceptives in practice?

Answer: The strongest, most litigated protections usually cluster in three buckets: combination composition/formulation, regimen/method-of-use, and manufacturing/process/stability.

Patent family types that repeatedly matter

1) Composition-of-matter (active and combinations)

• Specific progestin derivatives are less common for modern oral contraceptives than legacy actives, but combination compositions still generate claim coverage around defined ratios and chemical forms.

2) Formulation patents (unit dosage and stability)

• Film-coating systems
• Disintegration and dissolution profiles tied to excipient selection
• Particle size control and hygroscopicity management (particularly relevant for longer shelf life and consistent release)

3) Method-of-use and regimen patents

• Extended-cycle schedules
• Defined dosing patterns (triphasic and quadriphasic sequences)
• Indication expansion that ties into contraceptive use plus additional claims where present

4) Manufacturing/process patents

• Tablet compression or granulation parameters
• Stability-improving manufacturing steps

Hitting the same target from different angles

Even when the active ingredient is off-patent, formulation and regimen patents can keep a brand active in the “protected” set for years, especially where courts treat certain claims as product-specific.

---

Which patent expiration dates and exclusivity timelines matter most for oral contraceptives?

Answer: Effective loss of exclusivity typically occurs when the last meaningful combination/formulation or regimen patent expires and any regulatory exclusivity window closes.

Practical timeline framework used in market planning

• Earlier horizon (often 0 to 5 years): Composition-of-matter and core combination formulation families begin to run out.
• Later horizon (often 5 to 10+ years): Regimen and formulation/process improvements maintain brand exclusivity for extended-cycle or lower-dose branded variants.

What to measure when building a launch plan

• Last expiration among:
  • Orange Book listed patents for the branded product’s NDC(s)
  • Any separately listed patents for the same brand across strengths/regimens
• Litigation status:
  • Pending injunction motions
  • Stayed approval and settlement entry dates

---

What is the Orange Book status of oral synthetic contraceptives?

Answer: Most branded oral synthetic contraceptives maintain Orange Book listings for multiple patent types across dosage forms and strengths, typically including composition/formulation and sometimes method-of-use.

How Orange Book listings translate into generic launch constraints

• Multiple listed patents can cause:
  • sequential litigation filings
  • staggered “carveout” strategies if the generic offers a different strength or regimen than the asserted product
• Brands can also benefit from:
  • additional listings for improved variants within the same product portfolio

---

How often do Paragraph IV challenges happen in oral contraceptives, and what drives outcomes?

Answer: Paragraph IV challenges occur regularly in the category, but outcomes depend on whether the asserted patents are formulation/regimen patents tied to the specific branded regimen and NDC.

Drivers of Paragraph IV success

• Patent weaknesses in claim scope due to:
  • earlier publication
  • obviousness/enablement vulnerabilities
  • generic ability to design around excipient or processing
• Fewer strong method-of-use claims for older legacy regimens.

Drivers of Paragraph IV failure

• Court treatment favoring product-specific formulation and stability claims
• Settlement leverage where the brand maintains multiple patent paths and avoids a single adverse ruling.

---

What patent litigation affects oral synthetic contraceptives most?

Answer: Litigation concentrates on fixed-dose combination-specific formulation and regimen claims rather than broad active-ingredient coverage.

Common litigation themes

• Generic ANDA “non-infringement” based on:
  • different formulation components
  • different release profile parameters
• Brand infringement assertions tied to:
  • stability and dissolution requirements
  • schedule and regimen method-of-use claims

Settlement patterns that matter commercially

• “60-day” exclusivity outcomes (if a generic is first to launch)
• Entry-date commitments that preserve brand revenue beyond nominal patent expiration
• License terms that trade early entry for ongoing payments or supply arrangements

---

How does patent strength compare between legacy EE-based products and newer progestin combinations?

Answer: Patent strength tends to be longer-lived for branded extended-cycle and optimized low-dose combinations, while legacy EE-progestin products more often face near-term generic penetration after the core combination formulation expires.

Comparison framework for decision-making

• Legacy products: Heavier generic competition; patents often already expired or limited to formulations that are easier to design around.
• Newer branded combinations: More likely to have:
  • layered regimen and formulation families
  • more complex dosing structures that reduce easy substitutions

---

Which companies typically hold and challenge IP in oral synthetic contraceptives?

Answer: The competitive field is characterized by brand-originator IP holders and a recurring set of generic manufacturers that file ANDAs and litigate against Orange Book patents.

Company roles

• Brand originators: Hold core combination portfolios and sustain evergreening via formulation/regimen families.
• Generic filers: Target high-volume brands; use Paragraph IV to force settlement or earlier launch.
• Authorized generics: Compete with brand through pricing pressure, often during post-cliff periods.

How to interpret “who is challenging” for market-entry risk

• Frequent Paragraph IV filers can accelerate generic normalization across multiple strengths.
• If challengers focus on specific NDCs, other strengths may remain protected longer.

---

What formulations are protected by patents for oral synthetic contraceptives?

Answer: Protected formulations typically focus on dosage unit architecture and release/stability design rather than cosmetic packaging.

Formulation claim targets with commercial impact

• Dissolution kinetics profiles meeting branded specifications
• Release characteristics that preserve hormone exposure equivalence
• Stability improvements enabling shelf-life extension
• Coating systems and excipient combinations

---

What method-of-use patents can block generic oral contraceptive entry?

Answer: Patents tied to dosing schedules and regimen use can block generic entry for claims framed around how the product is used, not only what it contains.

Regimen types most likely to trigger method-of-use protection

• Extended-cycle regimens
• Specific triphasic/quadriphasic sequences
• Continuous use schedules for symptom control where claimed

---

How do licensing deals and settlements reshape exclusivity in this category?

Answer: Licensing and settlements often determine the practical exclusivity date more than the nominal patent expiration calendar.

Settlement mechanics relevant to oral contraceptives

• Non-exclusive licenses that allow generic manufacturing but keep retail launch later
• Settlement entry dates mapped to the last asserted patent expiration
• Cross-licenses that reduce future litigation exposure across a portfolio

---

What generic entry risks exist for a new oral synthetic contraceptive launch?

Answer: The main risks are multipatent Orange Book coverage per regimen, method-of-use claim reach, and settlement pathways that shift launch dates beyond anticipated patent expiration.

Entry risk checklist for planning

• Confirm whether Orange Book lists include:
  • formulation/stability patents that are hard to design around
  • method-of-use patents covering dosing schedule claims
• Map whether litigation has already settled for the relevant NDC strength
• Identify whether multiple regimens under the same brand are independently protected.

---

How does the oral synthetic contraceptives competitive landscape compare across NDC strengths and regimens?

Answer: Competitive intensity varies by strength and regimen because each strength can carry distinct patent listings and different litigation histories.

Strength-by-strength outcomes

• Higher-complexity regimens (multi-phase schedules) are more likely to face regimen-specific patent coverage.
• Simpler single-phase combinations tend to show faster generic normalization after key formulation patents expire.

---

Key Takeaways

• Oral synthetic contraceptives operate in a mature market where brand value persists primarily through fixed-dose combination, regimen/method-of-use, and formulation/stability patent families.
• Generic entry is usually driven by ANDA + Orange Book listings + litigation outcomes, with settlements often determining real-world launch timing.
• Patent strength tends to be higher (and launch risk higher) for newer extended-cycle and optimized branded regimens than for legacy EE-progestin products, where core composition/formulation barriers often fall earlier.
• Competitive planning should treat exclusivity as an NDC- and regimen-specific variable, not a single “brand expiration” event.

---

FAQs

1. Which patent types most commonly block generic ANDA approval for oral contraceptive regimens?
2. How do extended-cycle dosing schedules affect infringement risk for generic oral contraceptives?
3. What Orange Book listing patterns indicate a longer-lived branded oral contraceptive patent estate?
4. Do settlements in oral contraceptives typically delay launch to the last asserted patent expiration or to a separate agreed date?
5. How do formulation and process patents change generic design-around strategies in oral synthetic contraceptives?

---

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Patent and Trademark Office. (n.d.). Patent search resources. https://patentscope.wipo.int/ and https://www.uspto.gov/patents/search